Wealth Alliance Biomarin Pharmaceutical Inc Transaction History

Wealth Alliance

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 30, 2024	SELL	$76.22 - $98.51 $18,978 - $24,528	-249 Reduced 10.23%	2,185 $210,000
Q3 2023 Nov 09, 2023	BUY	$85.07 - $94.48 $207,060 - $229,964	2,434 New	2,434 $215,000
Q4 2022 Feb 13, 2023	SELL	$80.93 - $108.63 $20,232 - $27,157	-250 Reduced 10.58%	2,112 $218,000
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $194,061 - $228,972	2,362 New	2,362 $200,000
Q1 2022 May 10, 2022	SELL	$74.28 - $92.69 $259,757 - $324,136	-3,497 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $13,913 - $17,745	194 Added 5.87%	3,497 $309,000
Q3 2021 Nov 12, 2021	BUY	$74.77 - $85.47 $12,785 - $14,615	171 Added 5.46%	3,303 $255,000
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $5,436 - $6,104	72 Added 2.35%	3,132 $261,000
Q1 2021 May 18, 2021	BUY	$74.73 - $90.69 $45,958 - $55,774	615 Added 25.15%	3,060 $231,000
Q4 2020 Feb 11, 2021	BUY	$72.61 - $90.2 $177,531 - $220,539	2,445 New	2,445 $214,000
Q3 2020 Nov 13, 2020	SELL	$71.87 - $131.03 $125,772 - $229,302	-1,750 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $139,212 - $217,385	1,750 New	1,750 $216,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Wealth Alliance, based on Form 13F filings with the SEC.

Stay updated on Wealth Alliance with notifications on news.